The use of a HEMOCHRON® JR. HEMONOX™ point of care test in monitoring the anticoagulant effects of enoxaparin during interventional coronary procedures

Journal of Thrombosis and Thrombolysis

Volumn 21, Issue 2, 2006, Pages 137-145

  El Rouby, Soumaya ^a   Cohen, Marc ^b   Gonzales, Andrea ^b   Hoppensteadt, Debra ^c   Lee, Ted ^a   Zucker, Marcia L ^a   Khalid, Khaula ^b   LaDuca, Frank M ^a   Fareed, Jawed ^c  

^a ITC   (United States)

^b NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Clot based point of care test; Enoxaparin; Percutaneous coronary intervention; Therapeutic anti Xa activity levels

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; BLOOD SAMPLING; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DEVICE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG MONITORING; DRUG RESPONSE; FEMALE; HEMATOCRIT; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; EVALUATION; HOSPITAL INFORMATION SYSTEM; INSTRUMENTATION; METHODOLOGY; MIDDLE AGED; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; DRUG MONITORING; ENOXAPARIN; FEMALE; HUMANS; MALE; MIDDLE AGED; POINT-OF-CARE SYSTEMS; WHOLE BLOOD COAGULATION TIME;

EID: 33645888387     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-006-4383-5     Document Type: Article

References (37)

1. Cohen M, Demers C, Gurfinkel EP, et al. (1997) A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group (ESSENCE). N Engl J Med 337:447-452
2. Antman EM, McCabe CH, Gurfinkel EP, et al. (1999) Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction TIMI-11B trial. Circulation 100:1593-1601
3. Goodman SG, Fitchett D, Armstrong PW, Langer A (2003) On behalf of the INTERACT Trial Investigators. The INTegrelin and Enoxaparin Randomized assessment of Acute Coronary syndrome Treatment Trial. Circulation 107:238-244
4. Cohen M (2003) The role of low-molecular-weight heparin in the management of acute coronary syndromes. J Am Coll Cardiol 41:55S-561S
5. Klein W, Buchwald A, Hillis WS, et al. (1997) Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study). Fragmin in Unstable Coronary Artery Disease. Circulation 4;80:30E-34E
6. Collet JP, Montalescot G, Lison L, et al. (2001) Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 103:658-663
7. Fox KAA, Antman EM, Cohen M, Bigonzi F (2002) For the ESSENCE/TIMI 11B Investigators. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention. Am J Cardiol 90:47-82
8. Aslam MS, Sundberg S, Sabri MN, Cooke D, Lakier JB (2002) Pharmacokinetic of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. Catheter Cardiovasc Interv 57:187-190
9. Ferguson JJ, Antman EM, Bates ER, et al. (2003) Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: Final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J 146:628-634
10. Lee DS, Bhatt DL, Moliterno DJ, Peacock WF, Ellis SG, Topol EJ (2004) The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients. J Invasive Cardiol 16:46-51
11. Ferguson JJ, Califf RM, Antman EM, et al. (2004) Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: Primary results of the SYNERGY randomized trial. JAMA 292:45-54
12. Rabah MM, Premmereur J, Graham M, et al. (1999) Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 84:139-195
13. Kereiakes DJ, Grines C, Fry E, et al. (2001) For the National Investigators Collaborating on Enoxaparin. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention: The NICE 1 and NICE 4 trials. J Invasive Cardiology 13:272-278
14. Chen WH, Lau CP, Lau YK, et al. (2002) Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention. J Invasive Cardiol 14:439-442
15. Choussat R, Montalescot G, Collet JP, et al. (2002) A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol 40:1943-1950
16. Wong GC, Giugliano RP, Antman EM (2003) Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. JAMA 289:331-342
17. Bhatt DL, Lee BI, Casterella PJ, et al. (2003) Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: Results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. J Am Coll Cardiol 41:20-25
18. Carnendran L, Borkowski R, Markabawi B, Warner MF (2003) Safety and efficacy of low-dose intravenous enoxaparin and GPIIb/IIIa inhibitor therapy during PCI. J Invasive Cardiol 15:235-238
19. Martin JL, Fry ET, Sanderink GJ, et al. (2004) Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv 61:163-170
20. Cziraky MJ, Spinler SA (1993) Low-molecular-weight heparins for the treatment of deep-vein thrombosis. Clin Pharm 12:892-899
21. Ramacciotti E, Araujo GR, Lastoria S, et al. (2004) An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis. Thromb Res 143:149-153
22. Marmur JD, Anand SX, Bagga RS, et al. (2003) The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Coll Cardiol 41:394-403
23. Lawrence M, Mixon TA, Cross D, Gantt DS, Dehmer GJ (2004) Assessment of anticoagulation using activated clotting times in patients receiving intravenous enoxaparin during percutaneous coronary intervention. Catheter Cardiovasc Interv 61:52-55
24. Graf J, Janssens U (2004) Low-molecular weight heparins in percutaneous coronary interventions: Current concepts, problems, and perspectives. Curr Pharm Des 10:375-386
25. Moliterno DJ, Hermiller JB, Kereiakes DJ, et al. (2003) A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study. J Am Coll Cardiol 42:1132-1139
26. Saw J, Kereiakes DJ, Mahaffey KW, et al. (2003) Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels. Thromb Res 112:301-306
27. Hoppensteadt DA, Jeske W, Fareed J, Bermes EW Jr (1995) The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagul Fibrinolysis (Suppl-1):S57-64
28. (1997) Dose-ranging trial of enoxaparin for unstable angina: Results of TIMI 11A. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. J Am Coll Cardiol 7:1474-1482
29. Leizorovicz A, Bara L, Samama MM, Haugh MC (1993) Factor Xa inhibition: Correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. Haemostasis 23(Suppl 1):89-98
30. Glenn NL, Fernando T (2004) Degree of anticoagulation after one subcutaneous and one subsequent intravenous booster dose of enoxaparin: implications for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. J Thromb Thrombolysis 17:167-171
31. Sie P, Aillaud MF, de Prost D, et al. (1987) Measurement of low molecular weight heparin ex vivo activities in clinical laboratories using various anti-Xa assays: Inter laboratory variability and requirement for an agreed low molecular weight heparin standard. Thromb Haemost 58:879-883
32. Depasse F, Gilbert M, Goret V, Rolland N, Samama MM (2000) Anti-Xa monitoring: Inter-assay variability. Thromb Haemost 84:1122-1123
33. Kovacs MJ, Keeney M (2000) Inter-assay and instrument variability of anti-Xa results. Thromb Haemost. 84:138
34. Gosselin RC, King JH, Janatpour KA, Dager WE, Larkin EC, Owings JT (2004) Variability of plasma anti-Xa activities with different lots of enoxaparin. Ann Pharmacother 38:563-568
35. Cohen M, Gonzales A, El Rouby S, et al. (2004) Monitoring of Enoxaparin during Interventional Coronary Procedures Using a HEMOCHRON® Jr. Hemonox ™ Point of Care Assay. Catheterization and Cardiovascular Interventions 62 No 1 Abstract #C12
36. Holmes MB, Schneider DJ, Hayes MG, Sobel BE, Mann KG (2000) Novel, bedside, tissue factor-dependent clotting assay permits improved assessment of combination antithrombotic and antiplatelet therapy. Circulation 24:102: 2051-2057
37. Diez J, El Rouby S, Hoppensteadt D, et al. (2005) Evaluation of the Anticoagulant Effect of Enoxaparin Using Clot Based Point of Care Tests. The XXth Congress of the International Society on Thrombosis and Haemostasis. J. Thromb Haemost 3, Abstract # 1023